24 results about "Inflammatory pain" patented technology

The invention relates to an application of a halophenol compound 2, 4 ', 5'-trihydroxy-5, 2 '-dibromo benzophenone in preparation of an analgesic drug. Experiments prove that the compound has a definite analgesic effect, can significantly inhibit mouse writhing reaction induced by acetic acid and II-phase inflammatory pain induced by formalin, and prolongs the thermal stimulation tail retraction incubation period, and the effect is superior to that of aspirin. Furthermore, in a nitroglycerin-induced migraine rat model, the compound can effectively improve behavioral symptoms and brain tissue pathological damage and remarkably regulate key index levels of CGRP, PGE2, ET-1, IL-1beta, IL-6, TNF-alpha, 5-HT and the like in plasma, which shows that the compound can be applied to preparation of analgesic drugs, preparation of drugs for treating migraine, preparation of drugs for treating migraine and the like. The invention particularly has important application value in medicines for preventing and / or treating migraine.

A transdermal patch for delivering lidocaine for pain relief comprises a backing layer, an adhesive layer, and a composition containing lidocaine in an amount ranging from about 1% to about 10% by weight and heparin as a non-anticoagulant permeation enhancer in an amount ranging from about 1% to about 50% by weight. The heparin enhances permeation of lidocaine through the skin without exerting systemic anticoagulant effects by temporarily disrupting lipid bilayers in the stratum corneum to create microchannels for increased diffusion of lidocaine molecules. The patch provides effective relief for multiple pain types including neuropathic pain, inflammatory pain, ischemic pain, post-surgical pain, nociplastic pain, mechanical pain, and compressive pain. The transdermal patch is configured to provide sustained release of lidocaine for periods ranging from about 8 hours to about 24 hours, reducing pain by at least 50% with minimal systemic absorption.

The present invention relates to a synergistic admixture of Gabapentin and Ketoprofen, preferably Ketoprofen Lysine, to a pharmaceutical composition comprising said admixtures and to the use of said admixtures or pharmaceutical compositions in the treatment of acute or chronic pain, in particular in the treatment of neuropathic or inflammatory pain.

The application relates to the technical field of pharmaceutical chemistry, and discloses a flurbiprofen ester enantiomer prodrug compound, a preparation method thereof, a pharmaceutical composition and purposes, the compound is (R)-AF377 or (S)-AF377, is formed by covalently connecting a carboxyl of (R)-flurbiprofen, (S)-flurbiprofen and a phenolic hydroxyl of acetaminophen through an ester bond, corresponding chiral carbons are R configuration and S configuration respectively, and structures are shown in formula (I) and formula (II). The application further provides a preparation method of the compound, a pharmaceutical composition containing the compound and purposes of the compound in pain, inflammation or fever treatment. The compound has high optical purity, releases an active ingredient in the liver, (S)-AF377 has synergistic anti-inflammatory analgesic activity, (R)-AF377 has independent analgesic activity, can reduce side effects of single drug use, improves bioavailability, and provides a new drug selection for treatment of mild to moderate inflammatory pain.

The invention belongs to the technical field of biological medicine, and particularly relates to synthesis and application of an oligopeptide compound. According to the invention, a plurality of methods are adopted to carry out structure optimization on WvVf-OCH3, and a series of WvVf-OCH3 structural optimization mutants with a relatively good inhibition effect on nAChRs are obtained. The mutant has excellent performance in the aspects of safety, stability and in-vivo efficacy, and has definite efficacy and development potential in the aspects of relieving muscle tension, removing wrinkles and relieving inflammatory pain. The WvVf-OCH3 mutant can be used as a candidate medicine for treating symptoms such as muscle tension, spasm and pain, or can be used as an active raw material of a medical beauty product with a wrinkle removing function.

The application discloses an indolone compound and a pharmaceutical composition and application thereof, and has a molecular structure as follows: the indolone compound has double activities of analgesia and antioxidation, can be used as an analgesic with an antioxidation function, and has application potential in inflammatory pain care.

The invention relates to the technical field of medicines, and particularly discloses application of 9-anthraformic acid in preparation of a non-addictive peripheral analgesic medicine. It is proved for the first time that 9-anthracene formic acid has a remarkable analgesic effect and can effectively relieve inflammatory pain, the action target is a peripheral part, central side effects such as addiction and respiratory depression of traditional opioid analgesic are avoided, gastrointestinal injury, cardiovascular risk and curative effect capping effect of non-steroidal anti-inflammatory drugs are also overcome, and the 9-anthracene formic acid can be applied to preparation of anti-inflammatory drugs. Animal experiments prove that the analgesic effect of the compound is comparable with that of classical opioid drug morphine, and a brand new candidate drug and an application direction are provided for developing novel non-addiction analgesic drugs.

The present application relates to the use of substituted indazoles for treatment and / or prophylaxis of allergic and / or inflammatory diseases in animals, especially for treatment and / or prophylaxis of atopic dermatitis, Flea Allergy Dermatitis, inflammatory bowel disease, osteoarthritis and inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis and endometritis in animals.

The application relates to the technical field of medicines, and particularly discloses a class of celecoxib derivatives, a preparation method and application thereof. The derivative is formed by connecting celecoxib and straight-chain amino acids through a chemical bond, and the straight-chain amino acids are glycine, gamma-aminobutyric acid and the like. The derivative or a pharmaceutically acceptable salt and a pharmaceutical composition thereof can be used for preparing medicines for preventing and / or treating pain or nervous system diseases. The derivative has excellent water solubility, strong COX-2 inhibitory activity, good analgesic activity and anti-inflammatory activity, has good analgesic effects on inflammatory pain, neuropathic pain and visceral pain and the like, and has a wide application prospect.

The application discloses application of anterior piriform cortex GABAergic neurons as an analgesic target point, and relates to the technical field of neuroscience and pain. GABA The application discloses that the neural loop (APC GABA →MD) from the anterior piriform cortex GABAergic neurons to the thalamic dorsal medial nucleus plays a key role in pain regulation. Experiments prove that the loop can not only relieve acute pain, but also has a significant analgesic effect on the clinical treatment of intractable chronic inflammatory pain and neuropathic pain models, and shows a wide treatment application prospect.

The invention discloses a compound which is characterized in that the molecular structure of the compound is as follows: the compound can effectively inhibit COX-2 activity and scavenge free radicals at a micromolar concentration level, has anti-inflammatory, anti-oxidation and analgesic effects, and can be used as a nursing agent for inflammatory pain.

The application discloses a painkilling preparation containing radix scophulariae and radix aconiti and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine. The preparation is a transdermal patch, which is composed of a backing layer, a drug depot layer and an anti-sticking layer. The drug depot layer contains traditional Chinese medicine active ingredients and patch auxiliaries such as pressure-sensitive adhesive and transdermal absorption accelerators. The traditional Chinese medicine active ingredients take radix scophulariae and radix aconiti as the core drug pair, and are supplemented with one or more of the following drugs: qi-regulating analgesic drugs, blood-removing qi-regulating drugs, blood-activating analgesic drugs, blood-stasis-removing analgesic drugs, warm-qi-activating cold-dispelling drugs, wind-dispelling cold-dispelling drugs and external analgesic drugs. The application is a modern traditional Chinese medicine external preparation prepared by a patch technology, and the drug can penetrate the skin and directly reach the lesion, thereby playing a therapeutic role on inflammatory pain, cancer pain and idiopathic pain. The preparation has the characteristics of large drug loading, good transdermal absorption, fast analgesic effect, long-acting effect and avoidance of oral toxicity risk.

The application discloses a kind of customized analgesic hydrogel and its preparation and application.Specifically, the application discloses a new analgesic target, screens suitable drugs, and according to the characteristics of drug molecules, two-step method is customized to obtain sustained-release analgesic hydrogel.The two-step method is specifically divided into the following: first, according to the structure of drug molecules, aldehyde-based hyaluronic acid is synthesized to realize chemical drug loading;Second, adjust the concentration of Schiff base to form a double grid environment to realize injectability.Load the inhibitory drug TAPI-1 for the new target ADAM17 of stomatognathic inflammatory pain, construct a drug delivery system with targeted delivery, sustained-release analgesia, local injection and long-acting effect.Compared with the prior art, the drug delivery system obtained by the application has excellent sustained-release performance, the prolonged drug release is consistent with the hyperalgesia window period of stomatognathic inflammatory pain, precise and effective pain management is achieved, and the operation is simple, and has good conversion application prospect.

This invention is in the field of medicinal chemistry. In particular, the invention relates to anew class of small-molecules having a piperazine or piperidine structure which function as either inhibitors of pan-T-type calcium channel activity (e.g., CaV3.1 voltage gated calcium channel activity) (e.g., CaV3.2 voltage gated calcium channel activity) (e.g., CaV3.3 voltage gated calcium channel activity) (e.g., depolarization-induced calcium influx) or specific inhibitors of CaV3.2 voltage gated calcium channel activity, and their use as therapeutics for the treatment and / or prevention of pan-T-type calcium channel related pain (e.g., CaV3.1 related pain) (e.g., CaV3.2 related pain) (e.g., CaV3.3 related pain) (e.g., HIV-associated peripheral sensory neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), spinal nerve ligation (SNL) induced neuropathy) (e.g., tonic, neuropathic, and / or inflammatory pain) and related conditions.

The invention provides application of mesaconitine in a medicine for treating chronic inflammatory pain and an extraction method of the mesaconitine, and belongs to the technical field of mesaconitine extraction. An acid alcohol-alkali alcohol gradient elution method is adopted for elution and impurity removal, the obtained extract is a mesaconitine monomer component, then column chromatography refining and purification are carried out, mesaconitine with the purity being 95% or above is obtained, the extracted component is single, the preparation quality can be accurately controlled, and pharmacokinetic research and reasonable medication are facilitated. And the new aconitine has a strong effect and provides a new target spot for analgesia.

The application discloses a new use of sildenafil and its salts in combination with ibuprofen. Through pharmacodynamics and toxicology experiments, the application first proposes and verifies that the combination of sildenafil and its salts (sildenafil citrate) and ibuprofen has a significant synergistic effect in treating inflammatory pain, and can effectively reduce the renal toxicity induced by long-term administration of ibuprofen. The application solves the problem that long-term or large-dose use of ibuprofen can induce significant renal toxicity, which seriously limits the long-term, standard and sufficient clinical application of ibuprofen. The composition provided by the application can enhance the analgesic effect of ibuprofen and reduce the renal toxicity of ibuprofen, and has important clinical conversion value and practical application prospect.

The invention discloses a novel application of an AMPK (adenosine monophosphate kinase) activator Aldometanib in preparation of a medicine for inhibiting inflammatory pain. The research finds that animal experiments prove that the AMPK activator Aldometanib can obviously activate p-AMPK, effectively relieve inflammatory pain, improve the pain threshold value and relieve inflammation, and is high in safety, wide in application range and free of obvious side effects. The invention also discloses a molecular mechanism of the Aldometanib for relieving pain, and finds that the Aldometanib reduces the expression of pro-inflammatory cytokines such as TNF-alpha, IL-1beta, IL-6, IL-8 and the like by activating p-AMPK and regulating an STAT3-BDNF-TrkB pathway, and also reduces the activation of microglial cells, thereby reducing the damage and sensitization of nerve cells and playing a role in easing pain. The application of the Aldometanib in the field of medicine is expanded, a safe and effective treatment strategy is provided for treatment of inflammatory pain, and the application has wide clinical application prospects and market value.

The present application relates to polypeptides, in particular to an animal toxin polypeptide and application thereof. The polypeptide is identified by RNA sequencing of centipede transcriptome, and bioinformatics screening and Motif scanning analysis of translated protein sequence. Experimental results show that SM-8 shows strong analgesic effect in various pain models, including hot plate test, acetic acid writhing test, formalin inflammatory pain model and migraine model, and the analgesic effect is equivalent to that of butorphanol tartrate and sumatriptan. Molecular mechanism research shows that SM-8 can regulate the expression of pain-related genes. Preliminary safety evaluation by mouse open field test shows that the polypeptide does not cause obvious toxic side effects, has good safety, and has good prospects for development into a new polypeptide analgesic drug.

The present disclosure relates to the use of anti-IL6 receptor antibodies to treat non-inflammatory pain in subjects with rheumatoid arthritis.

The application discloses application of high gold line orchid extract in preparation of medicines or health products for treating or relieving pain, wherein the high gold line orchid extract is at least one of high gold line orchid alcohol extract, high gold line orchid polysaccharide or monomer compound of macfarlanea glycoside. Experimental results show that the high gold line orchid alcohol extract, the high gold line orchid polysaccharide and the monomer compound of macfarlanea glycoside all have good in-vivo analgesic activity, can significantly inhibit acute or chronic pain caused by chemical stimulation and thermal stimulation, can effectively reduce the writhing frequency of mice induced by intraperitoneal injection of acetic acid, prolong the pain reaction time of mice, and improve the pain threshold of mice in a hot tail-flick test. The above results show that the high gold line orchid extract can be used for clinical drug treatment of various pains, especially inflammatory pain, or be prepared into health products for relieving pain.

The application relates to application of anagirine A in preparation of analgesic drugs, and relates to an anagirine A compound separated from anagallis arvensis, which is an analgesic drug with inhibitory effects on transient receptor potential cation channel subfamily M member 8 (TRPM8), voltage-gated potassium channel 1.2 (Kv1.2), voltage-gated potassium channel 1.3 (Kv1.3), transient receptor potential cation channel protein 6 (TRPC6) and voltage-gated calcium channel 2.1 (Cav2.1), and is specifically a drug for neuropathic pain, traumatic pain or inflammatory pain. The compound anagirine A in the application can be combined with multiple analgesic related target points, so that a synergistic effect is generated, the treatment effect is enhanced, and side effects and drug resistance are reduced.

The present application relates to a kind of pharmaceutical compositions for treating gout, comprising three groups of active ingredients and adjuvant, wherein the first group of active ingredients has the effect of inhibiting the generation of uric acid, including one or more of Cordyceps militaris, celery seed, galangal, chicory;The second group of active ingredients has the effect of accelerating the excretion of uric acid, including one or more of corn silk, Gyrinopsys pentaphylla, dandelion, coix seed, lotus leaf, Poria cocos, marine fish oligopeptide;The third group of active ingredients has the effect of relieving inflammatory pain, including one or more of Ampelopsis brevifolia leaf, papaya, radix puerariae.The pharmaceutical composition can be made into granules, tablets and other dosage forms, with good drug efficacy, convenient to take, no obvious toxic and side effects and other advantages.

The therapeutic device of the present invention consists of a support to be placed on the patient's skin and is made of specific nanocrystals that, when suitably activated, generate electromagnetic emissions that have beneficial effects on the patient's inflammatory, painful diseases and neuromuscular and postural adjustments.

The application discloses a small-molecule twin drug compound with synergistic analgesic effect, a pharmaceutical composition, a preparation method and application thereof. The twin drug molecule is formed by covalently connecting a drug A and a drug B, wherein the drug A is nefopam, and the drug B is gamma-aminobutyric acid (GABA) and an analogue thereof, including gabapentin, pregabalin, GABA, methoxycarbonyl-gamma-aminobutyric acid (MGB), and cligabalin. The analgesic efficacy of the twin drug molecule is superior to that of combined administration and single drug, the twin drug molecule can obviously improve various acute and chronic inflammatory pains and relieve peripheral neuropathic pain induced by paclitaxel, has higher anti-inflammatory activity than that of combined administration and single drug, and thus has the potential to treat pain, inflammation and inflammation-related diseases, and can effectively reduce the interaction between drugs and increase the medication compliance of patients.